<DOC>
	<DOCNO>NCT00940303</DOCNO>
	<brief_summary>This single arm study assess progression-free survival , feasibility use safety Avastin combination 5-FU/FA , oxaliplatin irinotecan ( FOLFOXIRI ) first line treatment patient metastatic colorectal cancer . Patients receive 12 bi-weekly cycle Avastin ( 5mg/kg iv ) combination standard neoadjuvant chemotherapy regimen follow 40 bi-weekly cycle Avastin plus 5-FU/FA . The anticipated time study treatment disease progression , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>OPAL Study : A Study Avastin ( Bevacizumab ) Combination With FOLFOXIRI Patients With Previously Untreated Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>adult patient , 1870 year age ; metastatic colorectal cancer schedule standard first line chemotherapy ; least 1 measurable lesion ; ECOG performance score 0 1. prior chemotherapy metastatic colorectal cancer ; prior ( neo ) adjuvant chemotherapy/radiotherapy nonmetastatic malignancy complete within 6 month prior study entry ; concomitant malignancy CRC ; history evidence CNS disease unrelated cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>